Novel biomarkers for early detection of renal function decline in type 2 diabetes: A prospective multicenter cohort study

Introduction

Diabetic nephropathy affects approximately 40% of patients with diabetes mellitus and represents the leading cause of end-stage renal disease (ESRD) globally, accounting for significant morbidity, mortality, and healthcare costs. The prevalence continues to rise parallel to the global diabetes epidemic, making early detection and intervention increasingly critical for improving patient outcomes and reducing the burden on healthcare systems. Traditional biomarkers for assessing renal function, particularly serum creatinine and its derived estimated glomerular filtration rate (eGFR), have significant limitations in detecting early kidney damage. Serum creatinine levels typically remain within normal ranges until approximately 50% of nephron function is lost, representing a substantial delay in diagnosis during which irreversible structural damage may occur. This insensitivity to early pathological changes limits the window for therapeutic intervention. Novel biomarkers reflecting different aspects of kidney pathophysiology have emerged as promising tools for earlier detection. Cystatin C, a cysteine protease inhibitor produced at a constant rate by all nucleated cells, offers advantages over creatinine as it is less affected by muscle mass, age, and diet. Tubular injury markers including NGAL, KIM-1, and L-FABP may detect damage before changes in glomerular filtration become apparent, potentially providing an earlier window for intervention. The present study aimed to systematically evaluate these novel biomarkers in a large prospective cohort of patients with type 2 diabetes, comparing their diagnostic and prognostic performance to conventional markers and assessing their utility in clinical practice.

Materials and Methods

Study Design and Population

This prospective multicenter cohort study was conducted across 12 academic medical centers in Japan between April 2019 and March 2023. The study protocol was approved by the institutional review boards of all participating centers, and written informed consent was obtained from all participants. Patients were eligible if they had confirmed type 2 diabetes mellitus (HbA1c ≥6.5% or on glucoselowering medications), age 30-75 years, and baseline eGFR >60 mL/min/1.73m². Exclusion criteria included nondiabetic kidney disease, acute kidney injury within 3 months, active malignancy, and pregnancy.

Biomarker Measurements

Blood and urine samples were collected at baseline and quarterly intervals throughout the 3-year follow-up period. Serum cystatin C was measured by particle-enhanced nephelometric immunoassay (Siemens Healthcare Diagnostics). Urinary NGAL was quantified using a chemiluminescent microparticle immunoassay (Abbott Diagnostics). KIM-1 was measured by enzyme-linked immunosorbent assay (R&D Systems), and L-FABP by latex agglutination immunoassay (CMIC Holdings). All assays demonstrated coefficients of variation <8% for both intra-assay and inter-assay precision.

Statistical Analysis

The primary endpoint was a composite of eGFR decline ≥30% from baseline or progression to ESRD requiring renal replacement therapy. Receiver operating characteristic (ROC) analysis was performed to assess discriminatory ability, with area under the curve (AUC) comparisons using DeLong's method. Time-to-event analysis employed Kaplan-Meier methods and Cox proportional hazards regression. Biomarker quartiles were used for hazard ratio calculations, adjusting for age, sex, baseline eGFR, HbA1c, and albuminuria. Statistical significance was set at p<0.05.

Results

Baseline Characteristics

A total of 847 patients were enrolled, with mean age 58.4±9.2 years and 54% male. Mean diabetes duration was 12.3±7.1 years, with baseline HbA1c 7.4±1.2%. Baseline eGFR was 78.4±12.6 mL/min/1.73m², and 42% had microalbuminuria at enrollment. During the 3-year followup, 156 patients (18.4%) met the primary endpoint, with median time to progression of 18.7 months.

Biomarker Performance

Cystatin C demonstrated superior discriminatory ability for predicting progression compared to serum creatinine (AUC 0.94 vs 0.72, p<0.001). Among tubular markers, NGAL showed the highest performance (AUC 0.89), followed by KIM-1 (AUC 0.84) and L-FABP (AUC 0.81). The combined four-biomarker panel achieved AUC 0.97 (95% CI 0.95-0.98), significantly outperforming any individual marker (Figure 1).

Temporal Dynamics

Analysis of biomarker trajectories revealed that NGAL elevation preceded significant creatinine rise by 8.3±2.1 months on average. KIM-1 showed early elevation at 6.8±2.4 months before creatinine changes, while L-FABP increased 5.2±1.9 months earlier. Cystatin C demonstrated intermediate timing, rising 4.1±1.6 months before creatinine. These temporal differences provide a critical window for early intervention.

Risk Stratification

Cox regression analysis revealed significant associations between elevated biomarkers and disease progression.

Hazard ratios for the highest versus lowest quartile were: cystatin C 4.2 (95% CI 2.8-6.3), NGAL 3.8 (95% CI 2.5-5.8), KIM-1 2.9 (95% CI 1.9-4.4), and L-FABP 2.4 (95% CI 1.6-3.6), all p<0.001 after multivariable adjustment. Patients with elevation of all four biomarkers had 8.7-fold increased risk compared to those with no elevations (Figure 3). Second, cost-effectiveness analyses are required to determine optimal biomarker testing frequency and combinations. Third, interventional studies are needed to confirm that biomarker-guided therapy improves clinical outcomes compared to standard care.

Conclusion

Multi-biomarker panels incorporating cystatin C, NGAL, KIM-1, and L-FABP enable significantly earlier detection of diabetic nephropathy progression compared to traditional serum creatinine, with NGAL providing an 8-month lead time for potential therapeutic intervention. Implementation of these biomarkers in clinical practice may improve outcomes through earlier identification of high-risk patients and timely initiation of nephroprotective therapies.

References

1. Alicic RZ, Rooney MT, Tuttle KR. Diabetic kidney disease: challenges, progress, and possibilities. Clin J Am Soc Nephrol. 2017;12(12):2032-2045.
2. Vaidya VS, Ferguson MA, Bonventre JV. Kidney injury molecule-1 outperforms traditional biomarkers of kidney injury in preclinical biomarker qualification studies. Nat Biotechnol. 2010;28(5):478-485.
3. Bolignano D, Donato V, Coppolino G, et al. Neutrophil gelatinase-associated lipocalin (NGAL) as a marker of kidney damage. Am J Kidney Dis. 2008;52(3):595-605.
4. Kamijo A, Sugaya T, Hikawa A, et al. Urinary livertype fatty acid binding protein as a useful biomarker in chronic kidney disease. Mol Cell Biochem. 2006;284(12):175-182.
5. Shlipak MG, Matsushita K, Ärnlöv J, et al. Cystatin C versus creatinine in determining risk based on kidney function. N Engl J Med. 2013;369(10):932-943.
6. Peralta CA, Shlipak MG, Judd S, et al. Detection of chronic kidney disease with creatinine, cystatin C, and urine albumin-to-creatinine ratio. JAMA Intern Med. 2011;171(18):1627-1633.
7. Devarajan P. Neutrophil gelatinase-associated lipocalin: a promising biomarker for human acute kidney injury. Biomark Med. 2010;4(2):265-280.